Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 4 , Pages 391-399 , July 2009

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

  • Guru Sonpavde, M.D.

      Affiliations

    • Texas Oncology, P.A. and U.S. Oncology Research, Houston, TX 77030, USA
    • Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    • Section of Medical Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    • Corresponding Author InformationCorresponding author. Tel.: +281-332-7505; fax: +281-332-8429
    • Received research funding from Pfizer, Inc. toward this research project and is on the Speakers' Bureau for Pfizer.
    • ,
  • Weiguo Jian, M.D.

      Affiliations

    • Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    • ,
  • Hao Liu, M.D.

      Affiliations

    • Division of Biostatistics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
    • ,
  • Meng-Fen Wu, M.S.

      Affiliations

    • Division of Biostatistics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
    • ,
  • Steven S. Shen, M.D., Ph.D.

      Affiliations

    • Department of Pathology, The Methodist Hospital, Houston, TX 77030, USA
    • ,
  • Seth P. Lerner, M.D.

      Affiliations

    • Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    • Received research funding from Pfizer, Inc. toward this research project.

Received 22 January 2008 ,Revised 3 March 2008 ,Accepted 9 March 2008.

References 

  1. von der Maase H, Senegelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–4608
  2. Witte RS, Elson P, Bono B, et al. Eastern Cooperative Oncology Group Phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol. 1997;15:589–593
  3. Sweeney CJ, Roth BJ, Kabbinavar FF, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006;24(21):3451–3457
  4. Dreicer R, Gustin DM, See WA, et al. Paclitaxel in advanced urothelial carcinoma: Its role in patients with renal insufficiency and as salvage therapy. J Urol. 1996;156(5):1606–1608
  5. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997;15(5):1853–1857
  6. Winquist E, Vokes E, Moore MJ, et al. A Phase II study of oxaliplatin in urothelial cancer. Urol Oncol. 2005;23(3):150–154
  7. Crew JP, O'Brien T, Bradburn M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 1997;57(23):5281–5285
  8. Droller MJ. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. J Urol. 1998;160(5):1932
  9. O'Brien T, Cranston D, Fuggle S, et al. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res. 1995;55(3):510–513
  10. Sato K, Sasaki R, Ogura Y, et al. Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer. Tohoku J Exp Med. 1998;185(3):173–184
  11. Streeter EH, Harris AL. Angiogenesis in bladder cancer—prognostic marker and target for future therapy. Surg Oncol. 2002;11(1/2):85–100[Review]
  12. Bochner BH, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: Relationship between microvessel density and tumor prognosis. J Natl Cancer Inst. 1995;87:1603–1612
  13. Chaudhary R, Bromley M, Clarke NW, et al. Prognostic relevance of micro-vessel density in cancer of the urinary bladder. Anticancer Res. 1999;19:3479–3484
  14. Bernardini S, Fauconnet S, Chabannes E, et al. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol. 2001;166:1275–1279
  15. Campbell SC, Volpert OV, Ivanovich M, et al. Molecular mediators of angiogenesis in bladder cancer. Cancer Res. 1998;58:1298–1304
  16. Inoue K, Slaton JW, Davis DW, et al. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with antivascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res. 2000;6:2635–2643
  17. Muramaki M, Miyake H, Hara I, et al. Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KoTCC-1 model. J Urol. 2004;172(4 Pt 1):1485–1489
  18. Krause S, Forster Y, Kraemer K, et al. Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine, and cisplatin. J Urol. 2005;174(1):328–331
  19. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327–337
  20. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101(9):3597–3605
  21. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib vs. interferon α in metastatic renal cell carcinoma. N Engl J Med. 2007;356(2):115–124
  22. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: A randomized controlled trial. Lancet. 2006;368(9544):1329–133814
  23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1/2):55–63
  24. Harris JC, Gilliam AD, McKenzie AJ, et al. The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas. Cancer Res. 2004;64(16):5624–5631
  25. Diggle P, Heagerty P, Liang KY, et al. Analysis of Longitudinal Data. In: 2nd ed.. Oxford: University Press; 2002;p. 243–281
  26. Potapova O, Laird AD, Nannini MA, et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther. 2006;5(5):1280–1289
  27. Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2:471–478
  28. Gallagher DJ, Milowsky MI, Gerst SR, et al. Phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC). J Clin Oncol (June 20 Supplement) 5080. Proceedings of the 2007 ASCO Annual Meeting Part I, Vol 25, No. 18S, Chicago, IL, June 2007.

PII: S1078-1439(08)00069-0

doi: 10.1016/j.urolonc.2008.03.017

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 4 , Pages 391-399 , July 2009

Article Tools

* Image Usage & Resolution